Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: jont who wrote (724)	1/29/1999 12:55:00 PM
From: DEER HUNTER	Respond to of 1906

Thanks for the link to this site....it's a good one. Also....... biz.yahoo.com Friday January 29, 9:56 am Eastern Time RESEARCH ALERT - Amgen target price raised NEW YORK, Jan 29 (Reuters) - BT Alex. Brown said it raised Amgen Inc.'s (Nasdaq:AMGN - news) target price to $136 per share from $125 per share. -- The company said its fourth quarter earnings rose to $0.90 per diluted share from $0.67 the prior year. The better-than-expected performance was based on strong sales of Epogen, and Neupogen, the company's flagship products. -- The company also announced a 2-for-1 stock split in the form of a 100 percent stock dividend. -- BT Alex. Brown increased its EPS estimate to $3.65 from $3.54 and 2000 estimate to $4 from $3.86. -- Shares were up 5-1/8 at 124-11/16 on Friday.